A B S T R A C T Using cultured skin fibroblasts, we studied the heterogeneity of inborn errors of leucine metabolism such as isovaleric acidemia (IVA), glutaric aciduria type II (GA II), and multiple carboxylase deficiency (MC). We first developed a simple macromolecular-labeling test to measure the ability of cells to oxidize [1-`4C] 
from two different lines were fused using polyethylene glycol, and the ability of the heterokaryons to oxidize [1-'4C] isovaleric acid was tested by the macromolecularlabeling test. The MC line complemented with all 10 IVA lines tested; heterokaryons showed 99±68% more activity than the unfused mixture of component cells. GA II/IVA heterokaryons exhibited poor growth, but when the culture remained confluent, the GA II cells complemented with all six IVA lines tested, showing a 71±41% increase in activity. The relatively large standard deviations are due to a few experiments in which significant enhancement of macromolecular-labeling test activity was not observed upon fusion, but significant complementation was clearly observed in repeats of the same combinations. These results are consistent with our previous findings, which indicated that the decreased ability of GA II cells to oxidize isovaleryl-CoA involves a defective electron-transporting system rather than a defective isovaleryl-CoA dehydrogenase. IVA/IVA heterokaryons showed no complementation in any combination tested, indicating no detectable heterogeneity in isovaleric acidemia. This finding indicates that the same gene is mutated in all IVA lines. Previous results indicated that this gene codes for isovaleryl-CoA dehydrogenase.
INTRODUCTION
Several inborn errors involving leucine catabolism have been identified (1) . One of these is isovaleric acidemia (IVA),' in which the genetic defect occurs at the level of dehydrogenation of isovaleryl-CoA. This disease is clinically characterized by increased levels of isovaleric acid in the blood (2, 3) and by excessive urinary excretion of isovalerylglycine (4) . Episodic accumulation of isovaleric acid accompanied by severe vomiting, lethargy, coma, and ketoacidosis occurs in patients suf- fering from this inherited disease. Based on the pattern of metabolite accumulation (2, 4) and on in vitro studies of substrate oxidation using cells from IVA patients (5), a genetic mutation of a substrate-specific isovalerylCoA dehydrogenase in patients with IVA had been postulated. In fact, Rhead and Tanaka (6) recently demonstrated a specific deficiency of mitochondrial isovaleryl-CoA dehydrogenase activity in skin fibroblasts from patients with IVA using a tritium release assay devised for this purpose. In contrast, mitochondrial butyryl-CoA dehydrogenase activity in IVA cells was maintained at normal levels. These recent studies have elucidated the biochemical mechanisms of IVA. IVA appears to be transmitted by an autosomal recessive inheritance. This conclusion is supported by the occurrence in multiple sibs in many families, and approximately equal incidence in both sexes (1) The question of possible heterogeneity in IVA has frequently been raised from clinical standpoint because some patients exhibit severe acidosis immediately after birth (7) (8) (9) , while others have relatively mild symptoms that manifest themselves only later in childhood by mild acidosis (2, 3, 10, 11) . However, it is not yet known whether such variation in clinical expression is due to genetically determined heterogeneity or not.
Leucine metabolism is also blocked at the level of isovaleryl-CoA dehydrogenation in another inborn metabolic disorder, glutaric aciduria type II (GA II) (12) (13) (14) (15) . Like IVA, this disease is characterized by the excretion of large amounts of isovaleric acid, but unlike patients with IVA, several other short-chain fatty acids and dicarboxylic acids including glutaric, adipic, ethylmalonic, isobutyric, and 2-methylbutyric acids are excreted as well (12, 13, 15) . Thus, the defect in GA II comprises a wide range of metabolic reactions in which several different short-chain acyl-CoA, including isovaleryl-CoA, are dehydrogenated. From these observations it has been postulated that GA II is not due to a mutation of the various acyl-CoA dehydrogenases per se, but rather to a deficiency of one of the proteins involved in the transfer of electrons from acyl-CoA dehydrogenases to coenzyme Q of the mitochondrial electron transport chain (12) (13) (14) . Recent studies by Rhead et al. (14) and those by Goodman et al. (13) have shown that three acyl-CoA dehydrogenases (n-butyryl-CoA, isovaleryl-CoA, and glutarylCoA dehydrogenases) were in fact normal in GA II fibroblasts. Ethylmalonic-adipic aciduria (EMA) (16) is due to a similar mechanism, but its clinical manifestations are less severe than those of GA II.
To determine if there is any detectable genetic heterogeneity in IVA and to demonstrate that the defect in GA II involves a gene which is different from that for isovaleryl-CoA dehydrogenase, we developed a simple macromolecular-labeling test (MLT), which permitted us to undertake an extensive survey of the activity of enzymes involved in the oxidation of leucine after the production of isovaleryl-CoA. With this method we tested the ability of cultured skin fibroblasts obtained from patients with blocks in leucine catabolism to oxidize [1-_4C] MLTfor isovalerate oxidation. The MLT for isovalerate oxidation was similar to the method used by Willard et al. (19) to test the ability of cells to oxidize propionate. It is based on the following principles: in a normal cell, isovaleric acid labeled with a radioactive carbon at the carboxyl group is metabolized to unlabeled acetoacetic acid and labeled acetyl-CoA (Fig. 1) . When the labeled acetyl-CoA enters the tricarboxylic acid cycle, some of the radioactive label will appear in glutamic and aspartic acids via transamination of a-ketoglutaric and oxaloacetic acids, respectively (19, 20) . The labeled acetyl-CoA can also be used in the biosynthesis of fatty acids and cholesterol. All of these products can be in cold (0°-4°C) PBS and centrifuged at 4°C at 300 g for 20 min. The supernatant was aspirated and the cell pellet resuspended in 1.5 ml cold deionized water. To this suspension a 50% TCA solution was added to make a 10% final TCA concentration. A 10-min precipitation on ice followed. TCAprecipitable material was pelleted by centrifugation at 300 g for 5 min. The precipitate was solubilized in 0.5 ml 1 N NaOH and an aliquot was counted in Biofluor. The remainder of the sample was neutralized with HCI and used to determine protein concentration by the method of Lowry et al. (21) .
In the course of this study, two different batches of [1-'4C]isovaleric acid produced by custom synthesis by New England Nuclear were used as substrate. The first batch was sealed in several ampules and stored for 10 yr before use. When we switched to the new batch in the course of this study, we noted that the results of MLT obtained using the new substrate were approximately twice as high as those obtained with the old [1-'4C]isovaleric acid, even though the specific activity was adjusted as described in the preceeding section, but the power of segregating the normal and various mutant cell lines remained unchanged. Therefore, we carried out MLT on six normal cell lines using the old or new substrates and determined ratios of the two values. The range of these ratios in different cell lines were close, averaging 2.09±0. 31 . The values obtained using the old [1_i4C]isovaleric acid were then multiplied with this coefficient and combined to those obtained using the new [1-'4C]isovaleric acid.
Cell fusion. For complementation analysis, equal numbers of cells from two cell lines were mixed before plating.
Four tissue culture dishes were seeded with 1 X 106 cells/ plate. The next day, or after the dishes reached confluency, the medium was removed from two dishes and the monolayers were treated with a 50% (wt/vol) solution of autoclaved polyethylene glycol 6000 (PEG; J. T. Baker Chemical CO., Phillipsburg, NJ) in serum-free MEM for 60 s. After the PEG solution was removed, calcium-free medium (MEM suspension culture) was then applied to aid in reducing PEG toxicity (22) . The two remaining dishes were not treated with PEG but otherwise treated similarly. The two PEGuntreated plates served as controls. After 15 min the calciumfree medium was removed and 5 ml supplemented medium was added. Unless otherwise mentioned, cells were then incubated at 37°C for 16 h and at the end of this period reaction mixture for MLT was added and a 24-h incubation followed. Only the plates, which were near confluent, were harvested.
RESULTS
Oxidation of [1-14C] The MC line grown in the standard medium also showed a decreased ability to oxidize [1-_4C]isovalerate. The value was sufficiently low to enable us to use this line as a positive control in fusions with IVA cells in complementation studies, but in an effort to lower the activity of these cells, we tested the effect of avidin to exhaust the availability of biotin in culture media, since these cells were derived from a biotin-responsive patient. As can be seen in Table II , '4C incorporation dropped to 16% of the mean value obtained using the usual media. This is 5% of the mean of control values. In contrast, the amount of '4C incorporated by cells from two IVA lines grown in avidin-containing media dropped to 65% of the usual mean value, while normal cells from three lines grown in avidin media incorporated 72-92% the usual amount of 14C (data not shown).
We also tested the ability of cells from a patient with MSUD to oxidize [1-_4C] isovalerate. In this disease the block in leucine catabolism occurs at the step immediately preceding the dehydrogenation of isovaleryl-CoA (Fig. 1) (9, (23) (24) (25) , and others manifested symptoms of IVA later in childhood (10, 11, 19, 26) . Despite the large number of cell lines tested and the clinical heterogeneity of the patients from whom they were derived, we did not observe clear evidence for complementation in any combinations, including those of severe and mild types. These findings indicate that there was no intergenic complementation in the 12 IVA cell lines and suggest that the same gene coding for isovaleryl-CoA dehydrogenase is mutated in all IVA cells.
The finding that there is no detectable intergenic complementation in IVA is consistent with our recent characterization of the isovaleryl-CoA dehydrogenase purified from rat liver mitochondria. This enzyme has been completely separated from four other acyl-CoA dehydrogenases, including butyryl-CoA dehydrogenase, by a sequence of several chromatographic procedures (27, 28) . This enzyme is composed of four identical subunits of 43,000 D (28) . In other diseases, where clear genetic complementation has been previously found, such as propionic acidemia, methylmalonic acidemia, and MSUD, the enzymes involved are known to have multiple-component enzymes (29) , nonidentical subunits (30-32), or require a specific organic cofactor that must be biosynthesi7ed (33, 34) . Thus, the genetic heterogeneity in these diseases detected by complementation tests similar to ours are mostly due to mutation of genes encoding for different peptides.
When we compare the values in heterologous IVA (S/M) combinations with those in homologous (S/S or M/M) combinations, the mean MLT activities in fused and unfused cells were essentially identical. However, the frequency of small positive changes in the activity in fused cells was slightly greater (12/53) in the heterologous (S/M) combination group than in the homologous (S/S and M/M) combination group (8/63) Lastly, we examined IVA/GA II cell combinations. Although the GA II lines were difficult to grow, there was large enhancement of activity in fused cells in cultures that remained in good condition. This demonstrates that although the same step in leucine catabolism is blocked in both IVA and GA II, these two diseases are due to different mechanisms. This is consistent with the previous biochemical findings from this and other laboratories, which showed that the acylCoA dehydrogenases are normal in GA II cells (13, 14) . A more likely mechanism of this disease involves a defect in one of the electron transfer proteins, such as electron transfer flavoprotein, or electron transfer flavoprotein dehydrogenase, which carries electrons from the acyl-CoA dehydrogenase to coenzyme Q in the main mitochondrial electron transport chain (13, 14, 16) .
